Clinical trials: RRMS
Multiple Sclerosis, Relapsing-Remitting
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587715
- Testing
- Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells, Liberation therapy
- Where
- Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Multiple Sclerosis
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive…
- Trial name
- ADHERENCE (NCT03408093)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Volunteers
- 120 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
- Trial name
- NCT02555215
- Testing
- dimethyl fumarate
- Where
- 12 sites in United States, Belgium and 8 more
- Volunteers
- 20 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis (RRMS)
Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab
The goal of this proposal is to use the BeCare App to (1) determine changes in "Feel Good Effect", or "Restoring Physiologic Homeostasis(RPH)"for individuals with relapsing-remitting MS (RRMS) before and after starting…
- Trial name
- NCT05172466
- Testing
- BeCare application
- Where
- United States
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsing-remitting Multiple Sclerosis (RRMS)
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage.
- Trial name
- TWINS (NCT06663189)
- Testing
- treatment withdrawal, Usual DMT continuation, MRI
- Where
- 22 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis, Neurogenic Bladder
Vaginal Estriol in Multiple Sclerosis
Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS…
- Trial name
- NCT03774407
- Testing
- vaginal estriol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Texas Tech University Health Sciences Center
Multiple Sclerosis, Relapsing-Remitting
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
This is a prospective, non-interventional, multicenter study to evaluate quality of life (QoL) and influence of cognitive status on QoL in subjects with relapsing-remitting multiple sclerosis (RRMS) during two years of treatment…
- Trial name
- MusiClock (NCT01110993)
- Where
- Poland
- Volunteers
- 65 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- ReWRAP (NCT04002934)
- Testing
- Bazedoxifene Acetate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Riley Bove, MD
Multiple Sclerosis, Relapsing-Remitting
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- CLARITY (NCT00213135)
- Testing
- Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg
- Volunteers
- 1,326 people
- Sponsor
- EMD Serono
Relapsing-remitting Multiple Sclerosis
Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patients
the purpose of this study was to evaluate the usefulness of educational kinesiology program to improve cognitive impairement, manual dexterity and bimanual coordination in patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT07002151
- Testing
- educational kinesiology training program intervention for study group, conventional upper extremities coordination training for both arms experimental and comparator (study and control) groups
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Cairo University
Relapsing Remitting MS (RRMS)
Mental Rotation and Motor Imagery Training in Multiple Sclerosis
This randomized controlled trial investigated the effects of sequential laterality, motor imagery, and mental rotation training in individuals with relapsing-remitting multiple sclerosis.
- Trial name
- NCT07749690
- Testing
- Laterality, Motor Imagery, and Mental Rotation Training, Active Visual-Attention Control Training
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people
- Sponsor
- Abant Izzet Baysal University
Relapsing Remitting Multiple Sclerosis (RRMS)
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans.
- Trial name
- iPROACT-MS (NCT07318129)
- Testing
- Indole-3-propionic acid (IPA)
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Relapsing Remitting Multiple Sclerosis
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.
- Trial name
- NCT01541618
- Testing
- MSDX Complex-1 Biomarker test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MSDx, Inc.
Multiple Sclerosis, Relapsing-Remitting
Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS
This prospective study combining non conventional MRI techniques, neuropsychological screening tools, and a neurophysiological work-up using a sensitive and validated battery, will evaluate the predictive value of these measures…
- Trial name
- COGNIT-MS (NCT05510817)
- Testing
- Multiparametric assessment
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- University Hospital of Mont-Godinne
Multiple Sclerosis
VIGIP-SEP2: Training of Patients by Nurses on ADR Reporting by RRMS Patient Via an App
The patient's reporting of adverse drug reactions (ADRs) is recognized as being of interest for post-marketing safety monitoring, but is still underdeveloped in France, with an average lower than the European average.
- Trial name
- VIGIP-SEP2 (NCT04116424)
- Testing
- nurse training of the patient, neurologist accompaniement
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Caen
Relapsing Remitting Multiple Sclerosis (RRMS)
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
The primary objective of the study is to evaluate the evolution of walking capacity as measured by the timed 100-meter walk test (T100T), timed 25-foot walk test (T25FW), maximum walking distance (MWD), and Expanded Disability…
- Trial name
- TIMER (NCT00871780)
- Testing
- BG00002 (natalizumab)
- Where
- 15 sites in Belgium, Mexico and 4 more
- Volunteers
- 224 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
This is a phase IIa study in which GA Depot 80 or 40mg is administered as an IM injection to subjects with RRMS at 4 week intervals for 52 weeks of treatment.
- Trial name
- NCT02212886
- Testing
- GA Depot 80 mg, GA Depot 40 mg
- Where
- 3 sites in Israel
- Volunteers
- 25 people
- Sponsor
- Mapi Pharma Ltd.
Multiple Sclerosis, Relapsing Remitting
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
This is an observational, prospective, non-interventional, non-controlled study planned to be conducted in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01080053
- Where
- Argentina
- Volunteers
- 306 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587806
- Testing
- Autologous Bone Marrow-Derived Mononuclear Stem Cells, Liberation therapy
- Where
- 2 sites in India, Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP